Berenberg keeps a buy rating on AstraZeneca, targeting 140 pounds. However, it cut the 2025 free cash flow forecast by $3 billion, citing rising capital costs and delayed cash flow.
AstraZeneca and other European drugmakers are speeding up U.S. medicine shipments amid tariff concerns, with some firms stockpiling products for potential trade barriers.
AstraZeneca's CEO met with China's President Xi Jinping to boost foreign investment, highlighting concerns about economic stability and regulations, with Xi recognizing the role of foreign firms.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.